Improving outcomes in relapsed/refractory Non Hodgkin lymphoma (NHL)

Biospecific antibodies are showing promising activity in early phase trials in relapsed/refractory Non-Hodgkin lymphoma (NHL), including patients that have received prior CAR-T therapies. The first patient in the UK was dosed in Leicester in September with the novel CD19-41BBL antibody in the dose escalation phase. Due tothe complexity in delivery of this trial, the support of the Experimental Cancer Medicine Centre has been critical. Preliminary results from this trial were presented at ASH this month.